Introduction
High-dose radiotherapy (HDRT) has emerged as a pivotal therapeutic strategy in oncology, boasting prominent advantages [1–3]. It enables precise targeting of tumor foci, delivering ablative radiation doses to rapidly eradicate malignant cells while minimizing damage to adjacent normal tissues, thereby improving local tumor control rates and reducing treatment duration compared to conventional fractionated radiotherapy. Additionally, HDRT can trigger immunogenic cell death, releasing tumor-associated antigens to activate anti-tumor immune responses, laying a foundation for combined immunotherapy [4].
However, HDRT is not without limitations. It may induce severe acute and late toxicities, such as radiation pneumonitis or fibrosis, in normal organs with low radiation tolerance [5, 6]. Moreover, the ablative effect can disrupt the tumor microenvironment (TME), leading to an immunosuppressive state [7, 8].
A critical yet underemphasized issue is that HDRT mediates the infiltration of tumor-associated macrophages (TAMs) [9]. As key components of the TME, TAMs recruited post-HDRT often polarize into the M2 phenotype, which promotes tumor angiogenesis, invasion, and immune suppression, potentially counteracting the anti-tumor efficacy of HDRT and becoming a major obstacle to improving treatment outcomes.
In recent years, nanomedicine and catalysts have achieved remarkable progress in the field of tumor therapy research [10–19], distinguishing themselves with unique advantages such as high catalytic stability, tunable and controllable enzymatic activity, and excellent biocompatibility, which effectively overcome the inherent drawbacks of natural enzymes (e.g., poor stability, high cost, and easy degradation in vivo) [10, 17–28]. Current research on catalysts in tumor therapy has increasingly focused on their regulatory effects on the tumor microenvironment (TME), and a growing body of evidence from preclinical studies has confirmed their significant potential in modulating macrophage polarization [8, 29, 30]. Specifically, a variety of catalyst materials, including metal-organic framework (MOF)-based catalysts, high-entropy alloy catalysts, and metal oxide catalysts (e.g., iron oxide, cerium oxide), have been demonstrated to re-educate M2-type TAMs (the pro-tumorigenic phenotype) to the anti-tumor M1 phenotype through multiple pathways [27, 31, 32].
These pathways mainly involve regulating intracellular oxidative stress balance by scavenging excessive reactive oxygen species (ROS) or generating specific ROS, as well as modulating macrophage metabolic pathways such as glycolysis and oxidative phosphorylation [33]. This M2-to-M1 polarization of TAMs may not only effectively reverse the immunosuppressive TME induced by HDRT but also enhances the secretion of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and the presentation of tumor antigens by macrophages, thereby amplifying anti-tumor immune responses. Consequently, catalysts can synergistically boost the therapeutic efficacy of HDRT by remodeling the TME, which provides a promising and viable solution to overcome the limitations of HDRT in clinical tumor treatment.
Notably, tumor cells often exploit the CD47-SIRPα axis to escape immune surveillance, severely impairing macrophages’ anti-tumor potential [34, 35]. Overexpressed CD47 on tumor cells binds to SIRPα on macrophages, transmitting a “don’t eat me” signal that inhibits phagocytosis [36]. Even if catalysts polarize pro-tumor M2-type tumor-associated macrophages (TAMs) to anti-tumor M1 phenotype, the CD47-SIRPα-mediated immune escape still hinders effective phagocytosis.
Thus, to fully enhance the therapeutic efficacy of high-dose radiotherapy (HDRT), simultaneous blocking of the CD47 checkpoint is essential. Disrupting the CD47-SIRPα interaction relieves macrophages’ phagocytic inhibition, enabling efficient clearance of tumor cells and achieving synergistic enhancement with HDRT, which helps improve local tumor control and prevent recurrence.
Herein, we designed a novel macrophage membrane-camouflaged arginine catalyst particle (designated as MC) for sensitizing HDRT. The cubic arginine catalyst (CA) was synthesized via a co-precipitation method using aqueous solutions of arginine and chitosan at equimolar concentrations in the presence of iron ions (Scheme 1). Through experiments and theoretical calculations, we verified the excellent peroxidase (POD)-like activity of MC.
The macrophage membrane, which highly expresses SIRPα, enables targeting of tumor cell CD47 and inhibits CD47-SIRPα-mediated immune escape [37, 38]. In animal experiments, MC combined with HDRT efficiently killed tumors, generated substantial reactive oxygen species (ROS), induced immunogenic cell death (ICD), and promoted dendritic cells (DCs) maturation and T-cell activation. Furthermore, within the tumor microenvironment, MC polarized macrophages toward the M1 phenotype and competitively antagonized tumor cell CD47 to suppress immune escape, ultimately synergizing with T cells to enhance anti-tumor immunity.
The combination of MC and HDRT achieved a tumor inhibition rate exceeding 90% and significantly suppressed tumor recurrence post-HDRT. This represents the first catalyst system that promotes HDRT efficacy while ameliorating its side effects, offering new insights for the design of clinical radiosensitizing materials.
Scheme 1Schematic illustration of cubic arginine catalysts for enhanced cancer immunotherapy
Results and discussion
Preparation and characterization of MC
This cubic CA catalyst was synthesized via co-precipitation using an equimolar aqueous mixture of arginine and chitosan in the presence of iron ions. At the meantime, Fe-Chitosan Hybrid (FCH) catalyst was prepared under identical conditions while omitting arginine, for comparative study. As shown in transmission electron microscopy (TEM) images in Fig.
1A, FCH displayed uniform cubic structure with approximately 80 nm on the side length. CA also demonstrated similar structure as shown in Fig. 1B.
Further analysis of energy dispersive X-ray spectroscopy verified Fe, C, N and O elements in CA (Fig. 1C). Additionally, X-ray photoelectron spectroscopy (XPS) also confirmed the existence of C 1s, N 1s, O 1s and Fe 2p peaks in CA (Fig.
1D). High resolution XPS of Fe 2p in Fig. 1E verified the peaks of Fe3+ splited into 723.6 eV and 710.7 eV for Fe 2p1/2 and Fe 2p3/2 respectively while the signal of Fe 2p1/2 at 720.9 eV and Fe 2p3/2 at 708.0 eV attributed to Fe2+ with satellite peaks at 715.2 eV and 718.0 eV respectively.
Next, cells membrane was extracted for CA camouflaging. The zeta potential shifted from − 8.9 mV to -13.5 mV after MV coating (Fig. 1F).
Both the size of side length of CA and MC remianed stable during observation (Fig. 1G). The absorption curve of MC was demonstrated in Fig.
1H. As shown in Fig. 1I, the successful incorporation of the MV coating onto the CA catalyst was confirmed by Fourier transform infrared (FTIR) spectroscopy.
Both the MV and MC spectra show strong protein signals of N-H/OH at 3418 cm− 1, amide I/II/III bands at 1653 cm− 1, 1556 cm− 1, 1240 cm− 1. Key lipid featured in MC include C-H stretch at 2939 cm− 1, a split ester C = O peak, and P-O-C vibration at 1053 cm− 1, confirming MV was successfully coated on CA. The spectrum of the final MC composite exhibits all the key absorption features of the native MV.
Meanwhile, the TEM images of MC in Fig. 1J proved a distinct surface coating structure with a thickness of approximately 5 nm, confirming the successful camouflaging of MV on CA. The result of Western blot analysis of CA, MV and MC in Fig.
1K confirmed the SIRPa and Na-K-ATPase protein in MC which was identical with MV pattern, which provides a foundation for tumor-targeting experiments. Combining TEM, zeta potential, FTIR and WB results, we fully confirmed intact macrophage membrane coating.
Fig. 1Characterization of MC. (A) TEM images of Fe-Chitosan Hybrid (FCH) and (B) CA.
(C) EDS of CA. (D) XPS survey and (E) high-resolution XPS of Fe 2p. (F) Zeta potential of indicated formulations.
(G) Average diameter of MC and CA in 10% FBS solution. (H) UV-vis spectra of MC. (I) FTIR spectra of MC and CA.
(J) TEM images of MC. (K) Western blot analysis. i: SIRPa; ii: Na-K-ATPase. The data are shown as the means ± SD (n = 3)
Validation of the multienzyme-mimicking activities of MC
To elucidate the enzymatic foundation for its potential biomedical applications, we systematically evaluated the inherent enzyme-mimicking activities of MC including POD-, CAT-, and NOS-like functionalities (Fig. 2A). The POD-like activity which conversed of H2O2 into ROS was first confirmed.
As shown in Figures S1 and S2, the addition of MC to a H2O2 solution induced a rapid and pronounced increase in the characteristic absorbance peak of oxidized TMB and HPF, demonstrating efficient catalytic property. Steady-state kinetic analysis fitted using Michaelis-Menten curves for both TMB and H2O2 substrates (Fig. 2B-E ), with calculated kinetic parameters of Km = 2.46 mM and Vmax = 0.26 µM·s− 1 for H2O2, indicating a high catalytic efficiency of MC.
Electron spin resonance (ESR) analysis further verified the generation of hydroxyl radicals by MC in presence of H2O2 (Fig. 2F), providing direct evidence of its POD-like activity.
Concurrently, MC exhibited significant CAT-like activity by decomposing H2O2 into O2 and H2O. Measurements of dissolved oxygen confirmed a substantial catalytic decomposition of H2O2 in the presence of MC (Fig. 2G).
Notably, MC also demonstrated potent NOS-like activity, catalyzing the sustained release of nitric oxide (NO) from an H2O2-containing environment (Fig. 2H). This NO-generating capability remained effective across a physiologically relevant pH range from 4.5 to 7.4, with no significant difference observed between different pH conditions (Fig.
2I), highlighting its catalytical stability. Collectively, these results confirm that MC intrinsically possesses robust and concurrent POD-, CAT-, and NOS-like activities.
Fig. 2Enzymic properties of MC. Assessment of (A) Schematic illustration of multienzyme mimicking properties of MC.
(B-C) Michaelis-Menten curves of MC with H2O2 as a substrate. (D-E) Michaelis-Menten curves of MC with H2O2 as a substrate. (F) ESR analysis of ·OH (2 mM H2O2).
(G) O2 production measurements. (H) NO release profile. (I) NO generation by MC across different pH level (2 mM H2O2).
The data are shown as the means ± SD (n = 3)
DFT calculations elucidating the catalytic mechanism of MC
To gain atomic-level insight into the origin of the multienzyme-mimicking activities observed experimentally, density functional theory (DFT) calculations were performed to simulate the catalytic pathways and evaluate the associated energy profiles for the POD-, CAT-, and NOS-like reactions on the MC catalyst. The proposed catalytic cycles are schematically illustrated in Fig. 3A-C.
For the CAT-like activity (Fig. 3A, D and G), the mechanism involves the sequential adsorption and dissociation of two H2O2 molecules on the active site. The calculated free energy profile reveals that the overall process of converting 2H2O2 to 2H2O and O2 is thermodynamically favorable.
The reaction proceeds through key intermediates (*H2O2, *O, *OHOOH, *O2), with the formation and subsequent dissociation of the *O2 intermediate to release O2 identified as a crucial step.
The NOS-like activity pathway, crucial for NO generation, is depicted in Fig. 3B, E and H. Owing to the catalytic cycle of natural NOS and leveraging the presence of arginine within MC, molecular O2 supplied in situ by the CAT-like activity is adsorbed and activated O2.
This activated O2 then reacts with the -C = NOH structure, transferring an oxygen atom to form a carbonyl group while releasing a NOH moiety. This NOH species is further stabilized on the metal center, undergoes protonation, and finally releases NO and H2O, completing the catalytic cycle.
Similarly, the mechanism for POD-like activity was investigated (Fig. 3C, F and I). The reaction initiates with H2O2 adsorption and homolytic cleavage to form two *OH species on the active site.
The subsequent reduction of these *OH radicals, coupled with proton transfer, leads to water formation and regeneration of the active site. The free energy profile for this pathway in Fig. 3F shows that the cleavage of *H2O2 and the reduction of *OH are energetically accessible steps, underpinning the catalyst’s ability to catalyze H2O2 into highly toxic ·OH radicals.
Collectively, the DFT calculations provide a coherent theoretical foundation for the experimentally validated multienzyme activities of MC. The favorable energy profiles for all three catalytic cycles demonstrate the intrinsic capability of the MC structure to facilitate key redox reactions involving H2O2 and O2, rationalizing its simultaneous POD-, CAT-, and NOS-like functionalities at the molecular level.
Fig. 3DFT calculations. Schematic illustration for (A) CAT-like catalytic reaction, (B) NOS-like catalytic reaction, and (C) POD-like catalytic reaction of MC.
Free energy profiles demonstrating (D) CAT-like activity, (E) NOS-like activity and (F) POD-like activity. Catalytic mechanism for (G) CAT-like path, (H) NOS-like path and (I) POD-like path
Synergistic effects of MC combined with HDRT in vitro
To elucidate the regulatory effects of different interventions on cellular iron metabolism, immune checkpoint expression, and radiotherapy-induced cellular damage, a series of in vitro analyses were performed. Our experimental results collectively demonstrate the distinct effects of different treatments on cellular responses. Figure 4A shows that the intracellular iron content increases significantly over time (0–12 h) in the MC group, indicating effective CA uptake, while the CA group shows negligible iron accumulation.
Figure 4B and C reveal that MC treatment drastically downregulates cell surface CD47 expression, with only 13.0% of cells remaining CD47-positive compared to 76.0% and 72.1% in the PBS and CA groups, respectively. In Fig. 4D, HPF fluorescence (a marker of reactive oxygen species, ROS) is minimal in the PBS group, weak in the RT and MC groups, and notably enhanced in the CA + RT group, with the strongest signal observed in the MC + RT group.
Similarly, Fig. 4E and G and Figure S3 illustrate that γH2AX foci (DNA damage), ATP and HMGB1 release, and CRT exposure are all most pronounced in the MC + RT group, followed by the CA + RT group. Taken together, these findings indicate that the combination of MC + RT synergistically induces higher levels of oxidative stress, DNA damage, and immunogenic cell death compared to other treatments.
As shown in Fig. 4H, the survival fraction of cancer cells demonstrated that MC treatment markedly suppressed tumor cell survival compared with the control group, and the combination of MC and radiotherapy (MC + RT) further aggravated cell death. Western blot results in Fig.
4I revealed that the expression of GPX4, a core inhibitory protein of ferroptosis, was gradually reduced in the order of PBS, RT, CA, MC, CA + RT, and MC + RT groups, indicating that MC synergized with radiation to downregulate GPX4 and thereby trigger ferroptosis. Transmission electron microscopy (TEM) images in Fig. 4J further provided morphological evidence of ferroptotic mitochondrial damage.
These data verify that MC exerts synergistic anti-tumor effects with radiotherapy via inducing robust ferroptosis in tumor cells.
To evaluate how different therapeutic interventions influence the activation of antigen-presenting cells and the polarization of inflammatory responses, we conducted a series of in vitro assays on dendritic cells (DCs) and macrophages. These experiments assess the activation of DCs and macrophages, along with the secretion of pro- and anti-inflammatory cytokines. Flow cytometry in Fig.
5A reveals that the proportion of CD80⁺CD86⁺ DCs rises progressively across treatment groups, with the highest percentage (50.3%) in the MC + RT group, followed by CA + RT (36.8%), MC (27.3%), RT (26.2%), and PBS (14.0%); this trend is reflected in Fig. 5B and E, where pro-inflammatory cytokines (TNF-α, IL-6, IL-12p70) are significantly elevated in the MC + RT group, indicating robust DC activation and pro-inflammatory cytokine release. For macrophage responses (Fig.
5F and K), flow cytometry in Fig. 5G shows that MC + H₂O₂ induces the highest proportion of F4/80⁺CD80⁺ macrophages (67.8%), surpassing CA (37.5%), MC (27.1%), and PBS (13.7%); cytokine analysis demonstrates that MC + H₂O₂ drastically reduces anti-inflammatory cytokines IL-10 and TGF-β (Fig. 5I and J) while strongly increasing pro-inflammatory IL-1β (Fig.
5K), suggesting that MC combined with oxidative stress shifts macrophages toward a pro-inflammatory phenotype. CA itself can also significantly promote macrophage polarization, possibly because CA is more easily engulfed by macrophages [39, 40]. Due to the presence of the cell membrane, MC is difficult to be phagocytosed by macrophages.
In the presence of hydrogen peroxide, it can generate reactive oxygen species to promote the polarization of macrophages. Taken together, these findings indicate that MC, especially when paired with radiotherapy or oxidative stress, potently activates DCs and polarizes macrophages to a pro-inflammatory state, thereby enhancing anti-tumor immunity through increased pro-inflammatory cytokine secretion and diminished anti-inflammatory signals. Transcriptomic profiling was performed to dissect transcriptional alterations induced by MC combined with radiotherapy (MC + RT).
The heatmap (Fig. 6A) displayed markedly divergent gene expression profiles between the Control and MC + RT groups, while the volcano plot (Fig. 6B) quantified numerous upregulated and downregulated differentially expressed genes (DEGs).
The PPI network mapped tight functional interactions among core DEGs (Fig. 6C). KEGG and GO enrichment bubble diagrams highlighted significant enrichment in immune signaling, lipid catabolism, oxidative stress and mesenchymal proliferation pathways (Figrues 6D and 6E), which was further supported by GSEA results of representative biological processes (Fig.
6F). Overall, these transcriptomic results confirm that MC + RT rewires tumor transcription programs by modulating immune activation, lipid metabolism and peroxide stress responses to generate synergistic antitumor activity.
Fig. 4Anti-tumor experiment in vitro. (A) Quantitative analysis of the cancer cell uptake of nanoparticles at different incubation time periods.
(B) CLSM images and (C) flow cytometry analysis of CD47 expression of cancer cells after incubated with different nanoparticles. Scale bars: 10 μm. (D) CLSM images and corresponding fluorescence intensity of HPF in cancer cells after different treatments.
Scale bars: 10 μm. (E) CLSM images and foci density of γ-H2AX in cancer cells after different treatments. Scale bars: 10 μm.
(F) HMGB1 expressions and HMGB1 release in U14 cells after different treatments. Scale bars: 10 μm. (G) CLSM images and corresponding fluorescence intensity of CRT expression in cancer cells after different treatments.
Scale bars: 10 μm. The data are shown as the means ± SD (n = 3). (H) Cell survival fraction of tumor cells after PBS, MC and combined MC + RT treatment.
(I) Western blot analysis of GPX4 protein expression in PBS, RT, CA, MC, CA + RT, and MC + RT groups. (J) TEM images of cellular ultrastructure in PBS, MC, and MC + RT groups. Statistical significance was calculated via one-way ANOVA with Tukey’s test: ***p < 0.001
Fig. 5Immune analysis in vitro. (A) Flow cytometry analysis and (B) Quantitative analysis of mature BMDCs after different treatments.
(C) The levels of TNF-⍺, (D) IL-6 and (E) IL-12p70 are secreted by matured BMDCs. (F) Schematic illustration of the macrophage polarization in vitro. (G) Flow cytometry analysis and (H) Quantitative analysis of M1 type macrophages (F4/80+CD80+) after different treatments.
(I) The levels of IL-10, (J) TGF-β and (K) IL-1β are secreted by macrophages. RT: 10 Gy. Data are shown as the mean ± SD (n = 3).
Statistical significance was calculated via one-way ANOVA with Tukey’s test: ns: Non-Significant, ***p < 0.001
Fig. 6Transcriptomic and functional enrichment analysis of DEGs in Control vs. MC + RT groups.
(A) Heatmap of top variable DEG expression. (B) Volcano plot of differential genes. (C) PPI network of key DEGs.
(D) KEGG enrichment bubble plot. (E) GO biological process enrichment bubble plot. (F) GSEA plots of eight representative biological processes and pathways
Synergistic effects of MC combined with HDRT in vivo
Then we systematically evaluates the therapeutic efficacy and underlying immunomodulatory mechanisms of different treatment regimens, including PBS, radiotherapy (RT), monotherapy (MC), and combined therapies (CA + RT, MC + RT), in a murine tumor model. Figure 7A and B demonstrate the in vivo biodistribution of CA and MC, showing that MC accumulates more persistently in tumors over 48 h while minimizing off-target retention in major organs. We also evaluated the hypoxia alleviation ability of CA and MC in tumor tissues.
As shown in Figure S4, green fluorescence signals representing hypoxia decreased significantly in tumors of mice received MC administration, proving the targeting ability and CAT-like activity of MC in vivo. The experimental timeline in Fig. 7C outlines the study design, involving tumor inoculation, treatment initiation, serial X-ray monitoring, and endpoint analysis.
Figure 7D–G quantify key therapeutic outcomes: MC + RT exhibits the most significant suppression of tumor growth, the greatest reduction in tumor weight, the longest survival duration, and no adverse impact on mouse body weight. Histological and immunofluorescence analyses in Fig. 7H (HE, TUNEL, γ-H2AX staining) confirm enhanced tumor cell apoptosis and DNA damage in the MC + RT group.
Figure 7I further shows that MC + RT robustly elevates the secretion of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6), indicating a potent activation of the antitumor immune response. Flow cytometry analyses (Fig. 7J and M) reveal that MC + RT treatment substantially increases the proportion of CD80⁺CD86⁺ mature dendritic cells, CD3⁺CD8⁺ cytotoxic T cells, and F4/80⁺CD80⁺ M1-like tumor-associated macrophages, collectively demonstrating that the combination therapy elicits a robust and coordinated antitumor immune response to achieve superior therapeutic efficacy.
Immunofluorescence results revealed that MC treatment markedly elevated CD86-positive M1 macrophage proportion while reducing CD206-positive M2 macrophages in tumor tissue (Fig. 8A and B). It is worth noting that HDRT alone significantly increased the proportion of M2-type macrophages, which is consistent with the results of previous studies [41, 42].
Although HDRT can promote ICD to activate T cells, M2-type macrophages do limit the function of T cells, thus resulting in poor therapeutic effects.
Then we investigated the therapeutic efficacy and immunomodulatory effects of a combined radiotherapy (RT) regimen with a manganese-based nanotherapeutic (MC) versus a control agent (CA) in a murine model of residual U14 tumor. In Fig. 9A, the experimental timeline outlines tumor inoculation via U14 cell injection on Day − 7, surgical removal of primary tumors on Day 0, and subsequent systemic administration of PBS, RT, MC, CA + RT, or MC + RT on Days 1, 3, and 5, with monitoring extending to Day 15.
Figure 9B demonstrates that MC + RT most potently suppressed residual tumor growth over 15 days, outperforming PBS, RT, MC, and CA + RT groups. This was accompanied by the lowest residual tumor weight in the MC + RT cohort (Fig. 9C) and the longest overall survival (Fig.
9D), whereas body weight remained stable across all groups (Fig. 9E) as well as no major injuries in main organs (Figure S5), indicating minimal systemic toxicity.
Immunofluorescence staining in Fig. 9F revealed the highest infiltration of CD8⁺ T cells in MC + RT-treated tumor tissues. Flow cytometry analysis (Fig.
9G) further confirmed that MC + RT significantly increased the proportion of CD44⁺CD62L⁺ effector memory T cells, a hallmark of durable anti-tumor immunity. Concurrently, Fig. 9H–K show that MC + RT robustly elevated the secretion of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, and IL-12p70) in serum, indicating a pronounced activation of the innate and adaptive immune systems.
MC + RT treatment elicits a synergistic anti-tumor response by enhancing tumor-infiltrating lymphocytes, promoting memory T cell formation, and amplifying pro-inflammatory cytokine release, thereby improving both local tumor control and systemic anti-tumor immunity.
Fig. 7In vivo anti-tumour study. (A) Pharmacokinetic curves of CA and MC.
(B) In vivo biodistribution of nanoparticles after injections. (C) Schematic diagram of therapy strategy. (D) Tumor volumes were measured every 3 days across all groups.
(E) Tumor weights were recorded for each treatment at the end of the study. (F) Survival curves after treatment. (G) Body weight were measured every 3 days across all groups.
(H) HE, TUNEL and γ-H2AX staining of tumor sections after the indicated treatments. Scale bars: 40 μm. (I) ELISA measurements of intratumorally secretions of IL-6, TNF-, and IFN-.
(J) Flow cytometry and quantitative analysis of DC maturation in LNs. (K) Flow cytometry and quantitative analysis of CD8+ T cells in tumors. (L) Flow cytometry and quantitative analysis of intratumoral M1-type macrophages.
(M) Flow cytometry and quantitative analysis of intratumoral M2-type macrophages. RT: 10 Gy. The data are presented as the means ± SDs.
The p values were calculated via one-way ANOVA, *p < 0.05, and ***p < 0.001
Fig. 8Representative immunofluorescence images of tumor tissues from PBS, RT, MC, CA + RT and MC + RT groups. (A) Co-staining of DAPI (nuclei, blue), CD86 (M1 macrophage marker, green) and F4/80 (pan-macrophage marker, red).
(B) Co-staining of DAPI (blue), CD206 (M2 macrophage marker, green) and F4/80 (red). Scale bars: 20 μm
Fig. 9Anti-tumor recurrence and metastasis. (A) Schematic illustration of the studies of recurrence U14 model therapy.
(B) Evolution of the tumor volume and (C) tumor weight after various treatments. (D) Survival curves after treatment. (E) Changes in body weight during the treatment period.
(F) CD8 staining of tumor sections after the indicated treatments. Scale bars: 40 μm. (G) Flow cytometry analysis and quantification of CD44+CD62L+ T lymphocytes in blood on the 7th day after the first treatment.
(H) ELISA measurements of TNF-, (I) IFN-, (J) IL-6 and (K) IL-12p70 in serum. Scale bars: 400 μm. Data are shown as the mean ± SD (n = 5).
Statistical significance was calculated via one-way ANOVA with Tukey’s test: ***p < 0.001
Conclusions
In summary, MC designed herein exerts a remarkable synergistic anti-tumor effect when combined with high-dose radiotherapy (HDRT), effectively addressing the key limitations of HDRT in clinical application. Specifically, MC not only possesses excellent peroxidase-like activity to generate reactive oxygen species for direct tumor killing but also targets the CD47-SIRPα axis through membrane-expressed SIRPα, successfully blocking tumor cell immune escape and promoting macrophage phagocytosis. More importantly, the MC-HDRT combination induces robust immunogenic cell death, accelerates dendritic cell maturation, activates T-cell responses, and reverses the pro-tumor M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype.
These synergistic effects collectively achieve over 90% tumor inhibition and significantly suppress post-HDRT tumor recurrence, verifying that MC is a promising radiosensitizing material capable of enhancing both the direct tumoricidal effect of HDRT and the anti-tumor immune response.
Despite promising results, future research should focus on several key aspects. First, systematic evaluation of MC’s long-term in vivo biocompatibility, biosafety, and metabolic pathways is essential for clinical translation. Second, in-depth mechanistic studies are needed to clarify the molecular interactions between MC and immune cells, as well as the regulatory network of its synergy with HDRT.
This study offers a novel approach to overcome HDRT limitations, and advancing MC-based radiosensitizing systems is expected to drive breakthroughs in malignant tumor treatment.
Supplementary Information
Supplementary Material 1